Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last

CNBCmarkets2026-11-19T09:57:53Z
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
PublisherCNBC
Categorymarkets
Published2026-11-19T09:57:53Z
Indexed5h ago
Read the full article at CNBC →

More from CNBC

Latest in markets

FinancePulse indexes headlines and short summaries from 20 institutional publishers. This page does not republish the full article — all rights belong to CNBC.